



Universiteit
Leiden
The Netherlands

X-linked hypophosphatemia management in adults: an international working group clinical practice guideline

Khan, A.A.; Ali, D.S.; Appelman-Dijkstra, N.M.; Carpenter, T.O.; Chaussain, C.; Imel, E.A.; ... ; Brandi, M.L.

Citation

Khan, A. A., Ali, D. S., Appelman-Dijkstra, N. M., Carpenter, T. O., Chaussain, C., Imel, E. A., ... Brandi, M. L. (2025). X-linked hypophosphatemia management in adults: an international working group clinical practice guideline. *The Journal Of Clinical Endocrinology & Metabolism*, 110(8), 2353-2370. doi:10.1210/clinem/dgaf170

Version: Publisher's Version
License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)
Downloaded from: <https://hdl.handle.net/1887/4299630>

Note: To cite this publication please use the final published version (if applicable).

X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline

Aliya A. Khan,¹ Dalal S. Ali,¹ Natasha M. Appelman-Dijkstra,² Thomas O. Carpenter,³ Catherine Chaussain,^{4,5,6} Erik A. Imel,⁷ Suzanne M. Jan de Beur,⁸ Pablo Florenzano,⁹ Hajar Abu Alrob,¹⁰ Rana Aldabagh,¹¹ R. Todd Alexander,¹² Farah Alsarraf,¹ Signe Sparre Beck-Nielsen,^{13,14} Martin Biosse-Duplan,^{4,5,6} Martine Cohen-Solal,¹⁵ Rachel K. Crowley,¹⁶ Karel Dandurand,¹⁷ Guido Filler,¹⁸ Lisa Friedlander,⁴ Seiji Fukumoto,¹⁹ Claudia Gagnon,^{20,21} Paul Goodyer,²² Corinna Grasemann,²³ Chelsey Grimbly,^{24,25} Salma Hussein,¹ Muhammad K. Javaid,²⁶ Sarah Khan,²⁷ Aneal Khan,²⁸ Anna Lehman,²⁹ Willem F. Lems,³⁰ E. Michael Lewiecki,³¹ Ciara McDonnell,^{32,33} Reza D. Mirza,¹⁰ Emmett Morgante,³⁴ Archibald Morrison,³⁵ Anthony A. Portale,³⁶ Yumie Rhee,³⁷ Eric T. Rush,^{38,39} Heide Siggelkow,^{40,41} Sotirios Tetradis,⁴² Laura Tosi,⁴³ Leanne M. Ward,⁴⁴ Gordon Guyatt,^{10,45,46} and Maria Luisa Brandi⁴⁷

¹Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON L8S 4L8, Canada

²Department of Internal Medicine, Division of Endocrinology, Center for Bone Quality, Leiden University Medical Center, Leiden 2300 ZA, the Netherlands

³Departments of Pediatrics (Endocrinology), and Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, CT 06520, USA

⁴Department of Oral Medicine, Faculty of Dentistry, UMR 1333, Université Paris Cité, Paris 75006, France

⁵Institut Imagine, INSERM 1163, 75015 Paris, France

⁶Department of Oral Medicine, APHP, Paris 75006, France

⁷Department of Medicine and Pediatrics, Endocrinology, Indiana University School of Medicine, Indianapolis, IN 46202, USA

⁸Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22903, USA

⁹Department of Endocrinology, School of Medicine Pontificia Universidad Católica de Chile, Santiago 8320165, Región Metropolitana, Chile

¹⁰Department of Health Research Methods, Evidence, and Impact at McMaster University, Hamilton, ON L8S 4L8, Canada

¹¹Faculty of Dentistry, University of Toronto, Toronto, ON M5G 2L3, Canada

¹²Faculty of Medicine & Dentistry, The University of Alberta, Edmonton, AB T6G 2R3, Canada

¹³Centre for Rare Diseases, Aarhus University Hospital, Aarhus N 8200, Denmark

¹⁴Department of Clinical Medicine, Aarhus University, Aarhus N 8200, Denmark

¹⁵Department of Rheumatology and reference center for Rare Bone Diseases, hopital Lariboisiere, Paris 75006, France

¹⁶Rare Disease Clinical Trial Network, University College Dublin, Dublin 4, D04 T6F4, Ireland

¹⁷Division of Internal Medicine, Endocrinology Division, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

¹⁸London Health Sciences Centre, Children's Hospital of Western Ontario, London, ON N6A 3K7, Canada

¹⁹Department of Medicine, Tamaki-Aozora Hospital, Tokushima 779-3125, Japan

²⁰Endocrinology and Nephrology Axis, CHU de Québec-Université Laval Research Centre, Québec, QC G1V 4G2, Canada

²¹Department of Medicine, Université Laval, Québec, QC G1V 0A6, Canada

²²Research Institute of the McGill University Health Centre, Montreal, QC H3H 2L9, Canada

²³Department of Pediatrics, Division of Rare Diseases, Katholisches Klinikum Bochum and Ruhr-University Bochum, 44791 Bochum, Germany

²⁴Department of Pediatrics, University of Alberta, Edmonton, AB T6G 2R3, Canada

²⁵Women and Children's Health Research Institute, Edmonton, AB T6G 1C9, Canada

²⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7HE, UK

²⁷Trillium Health Partners, University of Toronto, Toronto, ON L5M 2N1, Canada

²⁸M.A.G.I.C. Clinic (Metabolism and Genetics in Canada), Calgary, AB T2E 7Z4, Canada

²⁹Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z4, Canada

³⁰Department of Rheumatology, Amsterdam UMC, Amsterdam 1105 AZ, the Netherlands

³¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM 87106, USA

³²Department of Pediatric Endocrinology & Diabetes, Children's Health Ireland, Dublin D12 N512, Ireland

³³Department of Paediatrics, School of Medicine, University of Dublin, Trinity College, Dublin D02 PN40, Ireland

Received: 12 August 2024. Editorial Decision: 11 March 2025. Corrected and Typeset: 17 April 2025

© The Author(s) 2025. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.

³⁴Department of Kinesiology, University of Waterloo, Waterloo, ON N2L 3G1, Canada

³⁵Citadel Oral and Facial Surgery, Halifax, NS B3L 4H7, Canada

³⁶Department of Pediatrics, University of California San Francisco, San Francisco, CA 94115, USA

³⁷Endocrine Research Institute, Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea

³⁸Division of Clinical Genetics, Children's Mercy Kansas City, Kansas City, MO 64108, USA

³⁹Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO 64108-2792, USA

⁴⁰Department of Trauma, Orthopedics and Reconstructive Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany

⁴¹MVZ Endokrinologikum Goettingen, 37075 Goettingen, Germany

⁴²Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA 90095, USA

⁴³Department of Orthopedics, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA

⁴⁴Children's Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa, Ottawa, ON K1H 8L1, Canada

⁴⁵Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada

⁴⁶MAGIC Evidence Ecosystem Foundation [www.magicvidence.org], Oslo 0456, Norway

⁴⁷Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS, Milan 20132, Italy

Correspondence: Aliya Khan, MD, FRCPC, FACP, FACE, McMaster University, 223-3075 Hospital Gate, Oakville, ON L8M 1M1, Canada.

Email: aliya@mcmaster.ca, draliyakh@gmail.com

Abstract

Purpose: An international working group (IWG) consisting of experts in X-linked hypophosphatemia (XLH) developed global guidelines providing a comprehensive, evidence-based approach to XLH diagnosis, management, and monitoring.

Methods: The IWG, consisting of 43 members as well as methodologists and a patient partner, conducted 2 systematic reviews (SRs) and narrative reviews to address key areas. The SRs addressed the impact of burosumab compared to conventional therapy (phosphate and active vitamin D) or no therapy on patient-important outcomes in adults. They also evaluated conventional therapy compared to no therapy. GRADE methodology was applied to evaluate the certainty of evidence. Non-GRADED recommendations were made in the presence of insufficient evidence to conduct SRs. These guidelines have been reviewed and endorsed by several medical and patient societies and organizations.

Results: The diagnosis of XLH is based on integrating clinical evaluation, laboratory findings confirming renal phosphate wasting (following exclusion of conditions mimicking XLH), and skeletal imaging. Fibroblast growth factor 23 measurement and DNA analysis are of value in the diagnosis, if available. Pathogenic or likely pathogenic variants in the *PHEX* gene are confirmatory but not necessary for the diagnosis. Management requires a multidisciplinary team knowledgeable and experienced in XLH. Effective medical therapy with burosumab can improve fracture and pseudofracture healing.

Main Conclusion: In adults with XLH and fractures or pseudofractures, burosumab is recommended over no therapy (strong recommendation, GRADEd). Additionally, burosumab is suggested as the preferred treatment compared to conventional therapy (conditional recommendation, GRADEd) in the absence of fractures or pseudofractures. If burosumab is not available, symptomatic adults should be treated with conventional therapy (Non-GRADED recommendation).

Key Words: X-linked hypophosphatemia (XLH), clinical practice guidelines, consensus, adult XLH

Abbreviations: 1,25(OH)₂D, 1,25-dihydroxyvitamin D; aBMD, areal bone mineral density; AD, autosomal dominant; ALP, alkaline phosphatase; AR, autosomal recessive; BsALP, bone-specific alkaline phosphatase; CKD, chronic kidney disease; DXA, dual-energy x-ray absorptiometry; eGFR, estimated glomerular filtration rate; FGF23, fibroblast growth factor 23; GRADE, Grading of Recommendations, Assessment, Development, and Evaluation; HRQoL, health-related quality of life; IWG, international working group; MSK, musculoskeletal; PHEX, phosphate regulating endopeptidase homolog X-linked (gene); PTH, parathyroid hormone; QoL, quality of life; RCT, randomized controlled trial; SR, systematic review; TmP/GFR tubular maximum phosphate reabsorption adjusted for glomerular filtration rate; VUS, variant of uncertain significance; XLH, X-linked hypophosphatemia.

KEY GUIDANCE

GRADEd Recommendations

- **Development:** Developed following a structured approach
 - Treatment Recommendations: Based on systematic reviews.
 - Monitoring Recommendations: Based on an expert clinical practice survey (very low-quality evidence).
- **Expression of Recommendations:**
 - Strong Recommendations: expressed as **"We recommend."**
Strong: When the panel was confident that the desirable effects of the intervention outweighed the undesirable ones.
 - Weak/Conditional Recommendations: Expressed as **"We suggest."**
Weak: Attributed either to low certainty evidence

or to a close balance between the desirable and undesirable effects.

Conditional: When the panel concluded that the desirable effects of the intervention probably outweigh the undesirable effects, though there is some uncertainty.

Non-GRADED Recommendations

- **Development:** Based on a narrative review for questions where there was not sufficient evidence to conduct systematic reviews.
- **Expression of Recommendations:**
 - Expressed as **"The panel proposes."**

Consensus Development

All recommendations (GRADEd or non-GRADED) were developed through a consensus reached among the international working group (IWG) members across several meetings.

X-linked hypophosphatemia (XLH; OMIM 307800), is a rare genetic disorder caused by inactivating variants in the

phosphate regulating gene with homology to endopeptidases (*PHEX*) gene. This results in excess synthesis and secretion of fibroblast growth factor 23 (FGF23), which impairs proximal renal phosphate reabsorption causing renal phosphate wasting and hypophosphatemia. Excess FGF23 also reduces the 1- α hydroxylation of 25-hydroxyvitamin D (25(OH)D) to 1,25-dihydroxyvitamin D (1,25(OH)₂D) and increases catabolism of 1,25(OH)₂D by the upregulation of 24-hydroxylase. These effects lead to decreased absorption of phosphate from the bowel (1). Currently, there is limited data on the natural history of XLH as well as long-term outcomes; however, the burden of disease observed in the adult patient population suggests that late diagnosis and management are associated with adverse outcomes (2, 3). Adults present with osteomalacia, experience chronic musculoskeletal pain, lower limb deformity, fractures, pseudofractures, dental complications, fatigue, and difficulties with mobility and impaired physical function. Medical management includes conventional therapy with phosphate and active vitamin D, and more recently, burosumab (recombinant human IgG1 monoclonal antibody to FGF23) has become available (4).

The pivotal trial in adults comparing burosumab to placebo has demonstrated that burosumab enhanced fracture and pseudofracture healing by 16.8-fold compared to placebo ($P < .001$) (4). In this randomized controlled trial (RCT) burosumab demonstrated a significant reduction in stiffness in comparison to placebo (4). In asymptomatic adult patients with XLH, medical therapy (with either burosumab or phosphate and active vitamin D) is individualized based on symptoms as well as comorbidity.

Methodology

The recommendations in these guidelines are based on 2 systematic reviews (SRs) and an expert panel practice survey, in addition to a narrative review of the literature. The guidelines employed a rigorous approach, including a comprehensive literature review conducted by a specialized healthcare librarian, and duplicate assessment of eligibility, risk of bias, and data abstraction. The evaluation of the quality of evidence from included studies utilized the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology (5), and the SRs were preregistered with PROSPERO.

The GRADEd treatment recommendations followed a structured approach, encompassing the formulation of questions in the patient/intervention/comparator/outcome (PICO) format (6), conducting SRs, and rating the quality of evidence in “summary of findings tables” addressing patient-important outcomes (7). The recommendations were classified as strong or weak with a description of the quality of evidence (8, 9), patients’ values and preferences were taken into consideration for all recommendations. In contrast, the non-GRADEd recommendations did not adhere to a structured approach but were based on narrative reviews of the literature and consensus among the panelists. The phrase “*the panel proposes*” was used when presenting non-graded recommendations.

The GRADEd monitoring recommendations are supported by very low-quality evidence and were derived from a detailed expert practice survey. A threshold of 80% agreement among the surveyed experts was chosen as the necessary level to

recommend each clinical practice. More details are presented in an accompanying manuscript describing monitoring guidelines for XLH (citation pending publication).

HOW TO DIAGNOSE?

Diagnosis Recommendations in Adults (non-GRADEd)

The Panel Proposes

1. The panel proposes that the diagnosis of XLH be made in the presence of chronic hypophosphatemia in the absence of other conditions resulting in renal phosphate wasting. The diagnosis is supported by an X-linked inheritance pattern (see Fig. 1).

Initial assessment recommendations (GRADEd) (Fig. 2)

We suggest (weak recommendations, very low certainty evidence)*

1. Obtaining a history that includes documentation of XLH in the family, or an X-linked dominant inheritance pattern of hypophosphatemia; fractures or pseudofractures; and dental abscesses and/or periodontitis
2. Standing height, weight, and BMI measurements
3. Blood pressure measurements
4. Musculoskeletal examination for bony tenderness and range of motion
5. Measurements of serum phosphorus, calcium corrected for albumin, ALP, 25-hydroxyvitamin D, kidney function (creatinine, eGFR), TmP/GFR, PTH, 24-hour urine calcium and creatinine (or spot urine calcium and creatinine), 24-hour urine phosphorus and creatinine
6. Genetic testing for hypophosphatemia-associated genes, including *PHEX*
7. Baseline BMD assessment**
8. Baseline dental assessment with periapical x-rays or orthopantomogram to screen for enlarged pulp chambers, pulp necrosis, and periapical bone loss

*Based on clinical practice survey with 80% of experts performing the clinical practice 80% of the time in 80% or more of their patients attending for an initial assessment.

**Despite DXA limitations in XLH, BMD assessment may be of value in adults with skeletal mineralization abnormalities. In such individuals, serial assessment may be of value in the presence of hypogonadism or other conditions which can affect bone density, such as superimposed postmenopausal osteoporosis.

Abbreviations: ALP, alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; eGFR, estimated glomerular filtration rate; *PHEX* gene, phosphate regulating endopeptidase homolog X-linked gene; PTH, parathyroid hormone; TmP/GFR, tubular maximum phosphate reabsorption adjusted for glomerular filtration rate.




Figure 1. XLH diagnosis algorithm.

INITIAL ASSESSMENT RECOMMENDATIONS (NON-GRADED)

The Panel Proposes

1. At the initial assessment of an adult with XLH, a skeletal survey using plain x-rays is advised to detect asymptomatic pseudofractures. Bone scintigraphy may be used to further evaluate abnormalities if initial radiographs are inconclusive.
2. Evaluation of other possible causes of hypophosphatemia considering the differential (see Fig. 3).

Clinical manifestations, biochemical and radiographic evaluation. In adulthood, XLH is characterized by bone and joint pain, osteomalacia-related fractures or pseudofractures, early joint damage, enthesopathies, muscle weakness, lower limbs deformities, poor dental health, and hearing loss (Table 1) (3, 10). Adults with XLH experience progressive functional limitations, including stiffness and chronic pain as they age. This influences all spheres of quality of life (QoL), including work, travel, physical and mental health, as well as social and family life (10).

The key laboratory finding of XLH is persistently low fasting serum phosphorus. Calcium and parathyroid hormone (PTH) levels are usually normal, although PTH levels may be elevated in XLH. High doses of phosphate therapy contribute to further rises in PTH, leading to secondary and tertiary hyperparathyroidism (11–13). The 1,25(OH)₂D level may be low or inappropriately normal, alkaline phosphatase (ALP) may be high or normal, FGF23 levels may be high or inappropriately normal, and bone-specific ALP (BsALP) is usually normal or elevated reflecting the degree of osteomalacia

present. The tubular maximum phosphate reabsorption adjusted for glomerular filtration rate (TmP/GFR) is calculated using a fasting second void or 2-hour morning urine specimen with concurrent measurement of phosphorus and creatinine in the serum and urine; a low value is seen with renal phosphate wasting (14). Exclusion of other causes of renal phosphate wasting is required to confirm the diagnosis of XLH (Table 2) (15, 16).

Radiographic manifestations of XLH in adults may include the presence of osteomalacia-related fractures or pseudofractures, which are frequently present at sites of high mechanical stress. In addition, imaging is helpful in identifying early degenerative disc disease involving the spine as well as joint damage of the hips and knees characterized by syndesmophytes on the joint margins. Bone proliferation may occur at sites of ligament attachments, characterized as enthesopathies, or calcification in spinal ligaments (2, 23), and can in severe cases lead to spinal stenosis.

Role of genetic testing. XLH is confirmed by identification of a pathogenic or likely pathogenic *PHEX* variant when an X-linked dominant inheritance pattern is not evident in the family (24–26). In the case of an unknown genetic variant in the family, genetic testing may involve any form of testing that sequences the *PHEX* gene (single-gene sequencing, gene panels, whole-exome sequencing, and whole-genome sequencing) and the finding of a pathogenic or likely pathogenic variant in the *PHEX* gene can support the diagnosis of XLH. About one-third of patients do not have a recognized family history (27–30). Conventional *PHEX* gene sequencing may not reveal pathogenic mosaicism, deep intronic variants, chromosomal rearrangements, or other hereditary disorders

GRADEd Initial Assessment Recommendations in Adults




Figure 2. GRADEd initial assessment recommendations in adults with XLH.

of hypophosphatemia due to variants in *CYP27B1* (autosomal-recessive [AR] vitamin D dependent rickets type 1), *CYP2R1* (AR deficient vitamin D 25-hydroxylation), *DMP1* and *ENPP1* (AR hypophosphatemic rickets), *FAM20C* (AR Raine syndrome), *FGF23* (autosomal-dominant [AD] hypophosphatemic rickets), *SLC34A1* (AD hypophosphatemia with osteoporosis and nephrolithiasis; AR Fanconi syndrome), *SLC34A3* (AR/AD hereditary hypophosphatemic rickets with hypercalciuria) as well as *VDR* (AR vitamin D resistant rickets type 2A). Next-generation sequencing panels are now available for patients suspected of having heritable hypophosphatemia, although they may not yet be accessible in many countries. In some patients, DNA testing may be negative or may identify a variant of uncertain significance (VUS)—in these cases, the diagnosis of XLH relies on a clinical or biochemical diagnosis. When a de novo variant is identified, the family history may be negative. While there are technologies that can evaluate whether a VUS is damaging (for example if it is novel), these technologies are usually research-based and difficult to access. Since assessment of variants can change over time as new information becomes available, consideration can be given to re-interpretation of the variant classification in the future or assessment through a laboratory or specialist in variant interpretation.

Tumor-induced osteomalacia also results in FGF23-mediated renal phosphate wasting and should be considered in the differential diagnosis. It is caused by mesenchymal tumors which secrete FGF23 (31). Fanconi syndrome should be excluded by testing for aminoaciduria, glycosuria, normal anion gap metabolic acidosis, and low molecular weight proteinuria (10, 32, 33).

Role of bone histomorphometry. XLH is characterized by osteomalacia and peri-osteocytic “halo” lesions; the latter

may be useful in distinguishing XLH from tumor-induced osteomalacia (34). Peri-osteocytic lesions also suggest a possible XLH diagnosis in patients with an “XLH-like phenotype” but without a detectable *PHEX* pathogenic variant. Trans-iliac histomorphometry is useful in demonstrating the bone tissue effect of medical therapy (with either burosumab or phosphate and active vitamin D) (35).

Role of bone mineral density assessment. A dual-energy x-ray absorptiometry (DXA) study is widely used to assess areal bone mineral density (aBMD); however, its application in all patients with XLH requires careful interpretation and further evaluation (36). In adult patients with XLH, aBMD often appears falsely elevated at the lumbar spine and tends to be decreased at the hip and 1/3 radial site (37). The lumbar spine aBMD may be falsely elevated due to ligamentous ossification, enthesopathies, and lamina thickening (23, 38, 39). In addition, the increased cross-sectional bone area leads to an overestimation of the aBMD in both children and adults (23, 38, 39).

Despite these limitations, DXA may with cautious interpretation, still have clinical utility in fracture risk assessment, and it can also be of benefit in postmenopausal women and men over 50 who may have superimposed osteoporosis in association with aging and hypogonadism (37, 39).

WHO TO TREAT?

Natural History and Complications, Both Short-term and Long-term, and Impact of Therapy

Adults entering the XLH International Registry (NCT0319 3476) report high rates of skeletal symptoms/manifestations (71.8%) and problems with dentition (75.9% abscesses) (40). Some of these complications may respond to treatment and

Work up for Hypophosphatemia		Causes for Renal Phosphate wasting - TmP/GFR LOW	
		FGF23 HIGH	FGF23 LOW
1	Inadequate intake or absorption: • Malabsorption – small bowel (celiac, Crohn's) • Vitamin D deficiency • Gut phosphate binders • TmP/GFR high or normal	Loss of function <i>PHEX</i> gene: X-linked Hypophosphatemia (XLH)	Hereditary Hypophosphatemic Rickets with Hypercalciuria: Loss of function in Na-P Type 2c gene; leads to phosphaturia and hypercalciuria
2	Short term changes in serum phosphorus due to extracellular to intracellular shifts– influenced by insulin, glucose, catecholamines, rapid cell breakdown or growth or repair: • DKA treatment (insulin drives phosphate intracellular) • Refeeding syndrome • Hungry bone syndrome post parathyroidectomy • Acute respiratory alkalosis • Leukemia or lymphoma	<i>FGF23</i> gene variants (ADHR): leading to mutant FGF23, resistant to cleavage; low iron (Fe) increases FGF23 <i>DMP1</i>, <i>ENPP1</i>, <i>FAM20C</i> gene variants (ARHR): increase FGF23 expression <i>GNAS</i> gene variants (Fibrous Dysplasia/McCune-Albright Syndrome): can lead to high FGF23 levels	Fanconi Syndrome: Renal glycosuria, amino acid losses, renal tubular acidosis, urine phosphate losses Post Renal Transplant: Occurs in approximately 50% of cases
3	Renal phosphate wasting – TmP/GFR LOW	Tumor-Induced Osteomalacia: FGF23 excess produced by mesenchymal tumors IV iron (especially ferrous carboxymaltose)	Drugs: Aminoglycosides, cisplatin, tenofovir Heavy Metal Poisoning: Lead Paraproteinemia: Impairs renal tubular function Hyperparathyroidism: Decreased phosphate reabsorption

Abbreviations: DKA: diabetes ketoacidosis; FGF23: Fibroblast Growth Factor 23; TmP/GFR: TmP/GFR: Tubular maximum phosphate reabsorption adjusted for glomerular filtration rate

Figure 3. Workup for hypophosphatemia.

therefore, many experts recommend re-initiating medical therapy (with burosumab if available, or with conventional therapy if well tolerated) when clinical symptoms of osteomalacia, such as bone pain, osteomalacia-related fractures are present, during fracture healing of fractures or in preparation of skeletal/dental surgeries. In the adult population, the type and extent of previous treatment received will have an impact on the presence of current skeletal deformities as well as renal, parathyroid, and dental complications.

Treatment goals in adults are to normalize ALP, heal fractures, and improve bone pain and physical function. Normalization of fasting serum phosphorus is not in itself a treatment goal with conventional therapy. Treating with conventional therapy during adulthood may decrease but not eliminate dental abscesses or osteomalacia-related fractures. To date treatment in adulthood with conventional therapy or burosumab has not been shown to prevent or reverse the progression of enthesopathy or osteoarthritis. Conventional therapy in adulthood does not appear to be associated with excess cardiovascular risk (40, 41) but may be associated with chronic kidney disease (CKD), often in the presence of tertiary hyperparathyroidism (42). Only limited data are available regarding the effect of burosumab therapy on short-term patient outcomes in symptomatic adults (43).

Musculoskeletal Manifestations

Osteomalacia may result in bone and muscle pain as well as pseudofractures. Fractures and early osteoarthritis are also commonly observed (12, 44-47). An analysis study of clinical trial and survey data (n = 336) has shown that approximately 43% to 47% of adults with XLH had a history of fracture, with the proportions increasing with age (48). Joint damage occurs early and can be seen as early as the third decade. Bone pain, muscle pain, and muscle stiffness also contribute to decreased mobility. Enthesopathies initially manifest as calcification at the insertion sites of tendons and ligaments,

eventually progressing to osteophyte formation (49, 50). Enthesopathies often develop bilaterally, involving weight-bearing joints and the spine and result in significant pain and impaired mobility. Currently, medical therapy has not been shown to prevent or effectively treat enthesopathies (51). Healing of pseudofractures and improvement in histomorphometric indices occur with burosumab therapy compared to placebo (4, 52). Musculoskeletal pain, stiffness, and mobility particularly respond to therapy (4, 52, 53).

Renal Complications

Renal complications in XLH include nephrocalcinosis (54), urinary stone disease (54), CKD (55), and hypertension (55, 56). Prevalence of nephrocalcinosis varies from 21% to 42% (47, 57) and up to 100% in some series (58). Severe nephrocalcinosis may lead to end-stage renal disease (59). Hypercalcemia and aggressive overtreatment, with development of hyperphosphatemia or elevations in the calcium × phosphate product, may also contribute to CKD.

More severe disease, as ascertained by height Z-score, correlates with a higher incidence of nephrocalcinosis (54). The incidence and prevalence of urinary stone disease in these patients is not well described. The prevalence of hypertension correlates with lower estimated glomerular filtration rate (eGFR) and the presence of CKD (55). Excess sodium intake may also occur with the use of oral sodium phosphate salts and may also contribute to the development of hypertension (55, 59, 60). Multiple other factors may also contribute to hypertension in addition to CKD and include decreased physical activity, obesity, and possibly elevated FGF23 (56). Additional disease-specific factors, such as *PHEX* gene-associated downregulation of the sodium phosphate cotransporter 2 (NPT2) (61), require further evaluation.

Thus, it is essential to monitor for nephrocalcinosis and hypercalciuria (16); reductions in the dose of active vitamin D may reduce the hypercalciuria, which can be further treated with

Table 1. Clinical features of adult XLH

Lower limb deformity
Fractures and pseudofractures
Muscle weakness and fatigue
Bone and joint pain
Dental infections and periodontal disease
Early joint damage
Enthesopathies
Spinal stenosis
Tinnitus, hearing loss
Osteophytes

hydrochlorothiazide (62) and/or potassium citrate (63). The eGFR should be monitored using the average (64) of the modified Schwartz formula (65) and the Filler formula (66) for cystatin C in patients aged 1.5 to 25 years of age (67-69) and the CKD-EPI formula for older patients, using both creatinine and cystatin C (70). CKD should be treated as per regional guidelines. This includes the use of angiotensin-converting enzyme inhibitors or angiotensin-2 receptor blockers (71, 72).

Hypertension should be treated as per current guidelines using the latest country- or region-specific guidelines for pediatrics and adults, if available (71-74) recognizing the differences among the American and European guidelines (75). Burosumab therapy may lower the blood pressure (56).

Neurologic Manifestations

Neurological complications of XLH in adults include headaches, craniosynostosis, Chiari 1 malformation, syringomyelia, spinal stenosis, spinal cord compression, tinnitus, and hearing loss. In an ongoing, multinational, prospective, longitudinal study designed to characterize disease burden, progression and long-term outcomes in XLH (the X-linked Hypophosphatemia Disease Monitoring Program [XLH-DMP]), neurologic complications were reported in 364 affected adults (76). Craniosynostosis was reported in 33/364 (9%), Chiari type 1 malformation in 19/364 (5.2%), syringomyelia in 6/364 (1.6%), and severe headache in 72/364 (19.8%). Neurological manifestations that are found more frequently in adults than in children with XLH are spinal stenosis, seen in 67/364 (18.4%), and spinal cord compression, seen in 37/364 (10.2%). Spinal stenosis and spinal cord compression in XLH may result from ossification of the ligamentum flava, thickening of the laminae, hypertrophy of facet joints, and intervertebral disc calcification. The XLH-DMP reports common occurrences of tinnitus (126/364; 34.6%) and hearing loss (106/364; 29.1%) in adults with XLH. Thus, comprehensive neurological and fundoscopic examinations should be performed in the presence of headache or other neurologic symptoms.

Hearing

Hearing loss, most often asymmetric, affects up to 34% of affected adults (57). Both sensorineural and conductive hearing defects may arise. Underlying mechanisms appear to involve both endolymphatic hydrops as well as osteosclerosis and thickening of the petrous bone (77). There is insufficient

Table 2. Disorders with hypophosphatemia

Disease	OMIM number	Gene(s) involved
FGF23-dependent		
XLH (X-linked hypophosphatemia)	OMIM#307800	<i>PHEX</i>
ADHR (autosomal-dominant hypophosphatemic rickets)	OMIM#193100	<i>FGF23</i> <i>SKG3</i> (uncertain FGF23 status)
Autosomal-recessive hypophosphatemic rickets	OMIM#241520, #613312, 259775	<i>DMP1</i> , <i>ENPP1</i> , <i>FAM20C</i>
Hypophosphatemic rickets and hyperparathyroidism	OMIM#612089	<i>KLOTHO</i>
Osteoglyphonic dysplasia	OMIM#166250	<i>FGFR1</i>
Opsismodysplasia (17)	OMIM#258480	<i>INPPL1</i>
Cutaneous skeletal hypophosphatemia syndrome (RAS)	OMIM#163200	<i>RAS</i>
Fibrous Dysplasia	OMIM#174800	<i>GNAS</i>
Tumor-induced osteomalacia (TIO)	N/A	Various/N/A
IV iron (especially ferrous carboxymaltose)	N/A	N/A
FGF23-independent		
Hereditary hypophosphatemic rickets with hypercalciuria (18)	OMIM#241530	<i>SLC34A3</i>
Hypophosphatemia and nephrocalcinosis (19)	OMIM#182309	<i>SLC34A1</i>
X-linked recessive hypophosphatemic rickets: Dent disease (20)	OMIM#300009	<i>CLCN5</i>
Nephropathic cystinosis (21)	OMIM#219800	<i>CTNS</i>
Hypophosphatemia, nephrolithiasis, osteoporosis (22)	OMIM#604990	<i>NHERF1</i>

data at this time to assess the impact of treatment on the prevention and progression of hearing impairment.

Quality of Life

The burden of disease is significant in both children and adults with XLH, with the majority experiencing some degree of pain, joint stiffness, fatigue, and impaired mobility and physical function that interfere with daily life (47, 78-81) and increase with age (80). Health-related quality of life (HRQoL) is reduced in adults with XLH compared to the general population (2, 47, 81, 82), with the physical component being the most consistently affected (47, 79, 81, 82) although some studies also report lower mental health scores (81-83). In adults, conventional therapy was shown to improve bone or joint pain in a small uncontrolled study (84) and was associated with better mental health scores in a cross-sectional study (2). Burosumab reduced pain, improved stiffness, fatigue, and physical function, and improved walking distance; however, only the improvement in stiffness was significantly favorable compared to placebo at 24 weeks in the pivotal adult RCT (4). These improvements persisted at 48 and 96 weeks in the open-label extension of this study (43, 52). Small short-term uncontrolled studies also

have shown that burosumab improves muscle performance, fatigue, and pain (85) as well as stiffness, physical function, and the physical component of HRQoL (86).

Currently there is insufficient evidence to support a recommendation on the impact of conventional therapy (phosphate and active vitamin D) on QoL.

Metabolic Dysfunction

Obesity and metabolic dysfunction have been reported in some patients with hypophosphatemic rickets. In the XLH21 study, a total of 21 patients with XLH (53%) had insulin resistance (HOMA > 2.4, N = 10 conventional therapy, N = 11 burosumab) (56). Another cohort study involving 113 patients with XLH reported that 56% of patients were overweight or obese (87).

Monitoring recommendations: follow-UP (GRADEd) (Fig. 4)

The following assessments in adults are advised at least once a year unless otherwise specified:

We suggest (weak recommendations, very low certainty evidence)*

1. Pain assessment
2. Clinical assessment of fractures or pseudofractures by obtaining fracture history as well as physical examination for tenderness of regions with reported bone pain
3. Weight, standing height, and BMI measurement
4. Blood pressure measurement
5. Documentation of dental infections (abscesses or periodontitis) by history
6. Measurements of serum morning (fasting) phosphorus, total corrected or ionized calcium, ALP, creatinine or eGFR, PTH, 25-hydroxyvitamin D, spot urine phosphorus/creatinine ratio, spot urine calcium/creatinine ratio

Every 6 to 12 months:

7. Dental assessment
8. Clinical physical examination for skeletal deformity, osteoarthritis, and joint restriction

In the presence of neurological deficit:

9. Comprehensive neurological clinical examination

Annually or less frequent:

10. Renal imaging, preferably with renal ultrasound

Annually in the presence of bone pain:

11. Skeletal survey or x-rays to screen for fractures or pseudofractures

Practices that we suggest are not routinely required (discretionary):

12. Routine sitting height measurements
13. Routine QoL assessment

*Based on clinical practice survey with 80% of experts performing the clinical practice in 80% of their patients

Abbreviations: ALP, alkaline phosphatase; BMI, body mass index; eGFR, estimated glomerular filtration rate; PTH, parathyroid hormone; QoL, quality of life.

HOW TO TREAT?

Treatment recommendations* (GRADEd) (Fig. 5)

1. In adults with fractures or pseudofractures **we recommend** burosumab therapy over no therapy (*strong recommendation, moderate certainty*).
2. In adults without fractures or pseudofractures **we suggest** burosumab therapy over no therapy (*conditional recommendation, low certainty*).
3. In adults with fractures or pseudofractures **we suggest** burosumab therapy over conventional therapy (active vitamin D and phosphate salts) (*conditional recommendation, low certainty*).

*We recognize that there may be limitations to drug therapy accessibility.

TREATMENT RECOMMENDATIONS (NON-GRADED)

The Panel Proposes

1. Provide ongoing care by an expert in metabolic bone disease who recognizes the importance of multidisciplinary services at the transition to adulthood—along with patient support groups—to address disease-related comorbidities.
2. Continue medical therapy (with either burosumab or phosphate and active vitamin D) for at least several years following epiphyseal closure enabling the optimization of peak bone mass which occurs at approximately 20 to 25 years of age in asymptomatic individuals.
3. Provide medical therapy (with either burosumab or phosphate and active vitamin D) in the presence of symptoms or biochemical/histological evidence of osteomalacia (bone pain, weakness, osteomalacic fractures, elevated ALP, or osteomalacia on bone biopsy)
4. Optimize medical therapy (with either burosumab or phosphate and active vitamin D) prior to undertaking orthopedic surgeries or dental implant surgeries.
5. Provide ongoing adult care with pharmacotherapeutic management (with either burosumab or conventional therapy) with consideration of the benefits and risks of therapy and the patient's capacity for ongoing monitoring.
6. When treating with burosumab, adhere to the recommended starting dose and adjust doses to achieve serum phosphorus levels in the low to mid normal (peak) or just below the normal or low normal (trough) range for age, while avoiding hyperphosphatemia at any point in the dose cycle.
7. If burosumab is not available, symptomatic adults should be treated with conventional therapy (active vitamin D with or without phosphate salts).
8. Phosphate salts should not be used as monotherapy.
9. When treating with conventional therapy (active vitamin D with or without phosphate salts), the fasting serum phosphorus should not serve as a target. It is not necessary to achieve normal fasting serum phosphorus levels

- to treat XLH, and the high phosphate loads used to accomplish this often lead to severe hyperparathyroidism.
10. Treatment with active vitamin D and phosphate salts should be modified to avoid hypercalcemia and hypercalciuria.
 11. Burosumab is contraindicated in CKD (GFR less than 30 mL/min), and in acute kidney injury. Cautious use may be considered in the presence of an eGFR between 30 and 60 mL/min with careful monitoring.
 12. Treat hypertension using current regional recommendations pertaining to hypertension management.
 13. Treat tertiary hyperparathyroidism in the setting of hypercalcemia, where multi-gland involvement is anticipated, with off-label use of calcimimetics (ie, cinacalcet) to lower PTH levels, with careful monitoring of serum calcium to prevent hypocalcemia. If hyperparathyroidism and hypercalcemia remain uncontrolled, a subtotal parathyroidectomy should be considered.
 14. Treat hypercalciuria by reducing the dose of active vitamin D, and in persistent hypercalciuria, hydrochlorothiazide or potassium citrate may be used. The panel also proposes a low sodium intake (<1500 mg/day) and increased fluid intake up to 3 L/24 hours in the presence of hypercalciuria.
 15. Early referral to the spinal team with physiotherapy in cases of spinal scoliosis.
 16. Treat spinal scoliosis with surgical fixation if the Cobb angle is greater than 30 degrees depending on the rate of progression and location of the curve.

Conventional Therapy

Generally, symptomatic adults with XLH are treated with phosphate salts (750-2000 mg/day) divided into 3 to 4 doses daily, and active vitamin D (calcitriol [0.5 to 1 µg/day] or alfacalcidol [0.75-1.5 µg daily]), especially when treating osteomalacia or fractures. Doses may then be lowered during the maintenance phase of treatment to minimize long-term complications (11, 24, 49). A balanced use of calcitriol (useful in dampening PTH secretion) and phosphate is of value in order to avoid phosphate stimulation of PTH, which exacerbates renal phosphate loss and further lowers serum phosphate. Importantly, phosphate salts should not be used as monotherapy without concurrent active vitamin D. Active vitamin D without phosphate salts, however, may be considered in adults with mild symptoms.

Adequate dietary calcium intake is recommended to provide calcium for skeletal mineralization and the healing of osteomalacia and rickets, especially during the first few months of treatment, acknowledging that the active vitamin D also increases gastrointestinal calcium and phosphate absorption, and the combination may increase the risk of hypercalciuria. As calcium supplements act as phosphate binders, potentially reducing the bioavailability of phosphate supplements, calcium intake must be separated 1 hour from phosphate intake. Elevated PTH with concomitant low urinary Ca/Cr may indicate the need for increasing the calcium intake.

Phosphate supplementation is often limited by gastrointestinal tolerability issues, including dyspepsia, and a laxative effect. Patients may opt to discontinue phosphate replacement due to gastrointestinal side effects. As mentioned above, complications of conventional therapy include secondary and tertiary

(hypercalcemic) hyperparathyroidism, nephrocalcinosis, and CKD. Tertiary hyperparathyroidism occurs in about 25% to 30% of adults with XLH (88) and may develop several years after stopping conventional therapy. The resulting hypercalcemia limits the use of active vitamin D. Tertiary hyperparathyroidism usually requires multi-gland parathyroidectomy, and hypercalcemia can still recur. Cinacalcet may be effective as adjunctive therapy for hyperparathyroidism (89-91).

Burosumab

In adults, burosumab is administered at a starting dosing of 1 mg/kg every 4 weeks, with an approved maximum of 90 mg every 4 weeks, based on the dose used in the placebo-controlled trial in adults (4). This trial indicated that burosumab normalized serum phosphorus and the healing of active osteomalacia-related fractures (52). In the RCT comparing burosumab to placebo, burosumab positively impacted various QoL measures as noted above (4, 52, 92-94). However, when applying GRADE to assess the certainty of evidence with respect to QoL measures, burosumab showed little or no impact on fatigue or mobility. Burosumab also demonstrated probably little or no impact on pain and stiffness when using direct measures of pain and function. Dental abscesses appeared to be more with burosumab compared to placebo in the trial over 24 weeks (5% more; 95% CI, -5 to 16) (95).

Joint damage and enthesopathy are among the most debilitating symptoms of XLH in adults, beginning even in the third decade of life. Unfortunately, there is no evidence to date that either conventional therapy or burosumab in adults prevents joint damage or enthesopathy and further research is required.

Monitoring of burosumab requires frequent laboratory testing for both safety and efficacy as with conventional therapy. In contrast to conventional therapy, the target with burosumab is to achieve a normal fasting serum phosphorus concentration throughout the dose cycle, if possible, while avoiding hyperphosphatemia. Thus, the interpretation of every laboratory assessment requires consideration of its relationship in time to the last dose of burosumab. In clinical trials, the peak serum phosphorus value was observed at 7 days post-dose (53), while TmP/GFR peaked 7 to 14 days post-dose. Serum 1,25(OH)₂D peaks at day 3 to 7 after burosumab dose and the mean value is supraphysiologic. Hypercalciuria or hypercalcemia may theoretically occur early in the dosing cycle when or shortly after 1,25(OH)₂D levels peak, especially in patients with parathyroid autonomy or high calcium intake.

Achieving a normal fasting serum phosphorus throughout the dose cycle with burosumab is challenging and not all adults achieve normal fasting serum phosphorus with doses of up to 90 mg of burosumab every 4 weeks. In order to achieve consistently normal fasting serum phosphorus with burosumab therapy, some patients may require more frequent dosing than every 4 weeks and may require dosing every 2 weeks. The total monthly dose may be more than 90 mg in a 4-week period. These are currently off-label regimens. In contrast, some patients may require very low burosumab doses in order to normalize fasting serum phosphorus, highlighting the broad individual variation in response.

Complications of hyperparathyroidism in adults may be less likely to occur with burosumab. In a recent clinical trial reductions in PTH levels were noted with burosumab in comparison to placebo (52). Injection site reactions occur in adults

GRADEd Monitoring Recommendations in Adults




Figure 4. GRADEd monitoring recommendations for follow-up in adults with XLH.

GRADEd Treatment Recommendations in Adults




Figure 5. GRADEd treatment recommendations in adult XLH.

less commonly than in children and are typically brief and usually do not require discontinuation. Occasionally patients have reported transient generalized bone pain at the onset of therapy. About 8% (or more) of patients with XLH have restless legs syndrome in the absence of burosumab therapy. Restless leg syndrome has been noted as an adverse event of burosumab therapy (4).

Orthopedic and Related Surgical Procedures

Orthopedic intervention for XLH is predominately devoted to fracture care and osteotomies performed to correct limb alignment. Fractures and deformity occur primarily in the lower

extremities and are attributed to progressive osteomalacia and the impact of prolonged weight bearing on poorly mineralized bones and misaligned joints. Reports of surgical treatment of bone deformity in skeletally mature adults with XLH include small numbers of patients with no control groups. The few articles specific to surgical treatment in adults with XLH promote intramedullary fixation (rods) for realignment osteotomies to span the full length of the bone; this approach allows for long healing time and prevents recurrence of deformity over the long term. In general, however, surgical management should be coordinated between the surgical team and the metabolic bone disease specialists. For most skeletal surgeries, surgical healing of the bone is likely to be

improved with antecedent medical therapy (with either burosumab or phosphate and active vitamin D). Improved healing of active fractures after starting burosumab therapy was noted in the RCT study evaluating burosumab in comparison to placebo (before which many participants were receiving conventional therapy), supporting the use of burosumab for post-operative skeletal healing (4).

Pseudofractures

Pseudofractures are areas of weakened bone that appear as transverse radiolucent lines on imaging studies, varying in width from less than a millimeter to over a centimeter (96). They often indicate underlying skeletal weakness or dysfunction due to metabolic bone diseases such as osteomalacia. These lesions have been referred to as Looser's zones (97), insufficiency fractures (98), and osteomalacia-related fractures. The aims of therapy are to heal fractures and to prevent complications. If a pseudofracture is at high risk of progressing to a full-thickness fracture or worsening deformity, initiating burosumab therapy is advised. If burosumab is not available, conventional therapy should be considered, despite insufficient data on its impact on fracture healing. Strong evidence supporting the use of burosumab to enhance fracture or pseudofracture healing is available (4). Consider referral for surgery if there is evidence of deformity or severe pain that is not responding to medical therapy (with either burosumab or phosphate and active vitamin D). Complete fractures or pseudofractures may still require prolonged healing time, even with conventional therapy or burosumab, as noted in the RCT in which only 63% of the active fractures at baseline were completely healed at 48 weeks of therapy (52).

Complete fragility fracture

The goal of treatment is to fix the fracture, optimize the anatomy and function and promote recovery. The bone is likely to be soft in the presence of a mineralization defect, and therefore nailing may be preferable to plating. A specialized orthopedic team should be consulted in the presence of significant deformity that may be multi-planar. In the RCT improved radiographic healing of active fractures and pseudofractures was observed in the burosumab arm in comparison to placebo in adults over 24 weeks (4). In our accompanying systematic review, there was a 35% improvement in fracture and pseudofracture healing with a narrow CI (95% CI, 22 more to 49 more) with burosumab in comparison to placebo (95).

Other Elective Orthopedic Surgeries, Including Arthroplasty

If musculoskeletal pain is present, further evaluation is required to determine the cause. Advanced joint disease may require arthroplasty. A recent survey of musculoskeletal complaints in adults with XLH emphasized both the high frequency and early onset of musculoskeletal conditions, including osteoarthritis requiring hip and knee arthroplasty in adults as young as 30 years of age.

Scoliosis and spinal stenosis

Patients with scoliosis should be regularly monitored for progression as assessed by pain or worsening deformity.

Spinal stenosis is a complication of XLH and may require surgical intervention (48). Patients with XLH should be monitored for symptoms of neurologic compromise and undergo

spinal imaging in the presence of nerve or spinal cord compression with referral to surgical specialists. Patients may require laminectomy and spinal fusion procedures.

Patient Support Groups

Patient support groups play a crucial role in the care of adults with XLH. Organizations such as the XLH-Network (<https://xlhnetwork.org/>) and the Canadian XLH-Network (<https://canadianxlhnetwork.org/>), among others, provide valuable resources, education, community, and peer to peer support for patients of all ages. They offer information on disease management, transition from pediatric to adult care, and self-care strategies. They also provide valuable information regarding how and where to access specialized multidisciplinary team care. Support groups are of great value in assisting patients with XLH in navigating the healthcare system. Psychological support is also an unmet need and patient support groups may be of value in locating community resources (99, 100). By providing a platform for shared experiences and advocacy, patient support groups empower adults with XLH to take an active role in their healthcare and may contribute to improve their QoL.

PREGNANCY AND LACTATION

Preconception and pregnancy (GRADEd)

For follow-up assessment during preconception and pregnancy:

We suggest (weak recommendations, very low certainty evidence)*

1. Providing genetic counseling to all women of childbearing age, including adolescents, regarding the inheritance of XLH and the risk of transmission
2. Counseling women of childbearing age (including adolescents) who are treated with burosumab or conventional therapy (phosphate salts and active vitamin D) regarding the limited evidence of the risks and benefits associated with these treatments

In the presence of neurological deficit:

3. Conduct a comprehensive neurological clinical examination for patients presenting with neurological deficits

Biochemistry:

4. Measurement of serum total calcium (albumin corrected) or ionized once every trimester for all women; serum creatinine and eGFR measurement monthly for women on medical therapy; and fasting serum phosphorus at least once during pregnancy for all women.

Practices that we suggest are not routinely required during pregnancy (discretionary):

5. Mobility assessment with 6MWT during pregnancy
6. QoL assessment
7. Renal ultrasound to screen for nephrocalcinosis during pregnancy

*Based on clinical practice survey with 80% of experts performing the clinical practice in 80% of their patients.

Abbreviations: 6MWT, 6-minute walking test; eGFR, estimated glomerular filtration rate; QoL, quality of life.

RECOMMENDATIONS FOR PREGNANCY AND LACTATION (NON-GRADEd)

The Panel Proposes

1. Optimization/normalization of serum corrected calcium, and vitamin D levels preconception, during pregnancy, and while breastfeeding. This may involve considering surgical intervention pre-conception in cases of existing tertiary hyperparathyroidism (the ideal target for fasting serum phosphorus in pregnancy is not known at this time).
2. Medication review should be performed preconception:
 - (a) Thiazide diuretics, angiotensin-converting enzyme inhibitors or angiotensin-2 receptor blockers, should be stopped.
 - (b) Cinacalcet is not recommended during pregnancy (FDA category C). Data regarding the safety of cinacalcet in pregnancy is limited. It has been successfully used in nonpregnant individuals with XLH and hyperparathyroidism.
 - (c) Safety of burosumab treatment during pregnancy and lactation is not established. Risks and benefits of therapy should be discussed with patients. There is inadequate data at this time to make a recommendation regarding burosumab therapy during pregnancy.
3. Phosphate supplementation is ideally divided into 4 to 5 daily doses, and always in combination with active vitamin D, (calcitriol is given twice daily given the short half-life and alfacalcidol is given once daily).
4. Lower doses of phosphate and active vitamin D may be sufficient in pregnancy due to increased endogenous production of $1,25(\text{OH})_2\text{D}$. However, close monitoring is required, as requirements for conventional therapy may vary among patients.
5. Blood pressure monitoring at every pregnancy visit; and treatment for hypertension should be initiated in collaboration with the obstetrician, both preconception and during pregnancy. This should follow the current regional recommendations pertaining to hypertension management.
6. Close monitoring of serum corrected calcium during lactation with modifications of active vitamin D in cases with existing secondary/tertiary hyperparathyroidism, as hypercalcemia may worsen due to rises in parathyroid hormone-related protein (PTHrP).
7. Normalization of bone-specific alkaline phosphatase (BsALP) by ensuring adequate calcium intake, active vitamin D, and native vitamin D supplementation during pregnancy.
8. Monitoring breastfed infants of affected mothers to ensure their serum phosphorus levels are normal.

Preconception Planning. Women of childbearing age with XLH should receive preconception advice and multidisciplinary counseling regarding the inheritance pattern, and possible complications of pregnancy or drug therapy in XLH. The involvement of a genetic counselor is useful. Prenatal and preimplantation genetic testing for XLH may be considered as possible options in some contexts (101). In addition, the utilization of embryo selection may also be discussed if available and amenable.

Pregnancy and Lactation

Physiological changes. Pregnancy results in changes in calcium and phosphorus homeostasis. These changes are beneficial in supporting fetal skeletal development and growth and include elevations in parathyroid-related protein (PTHrP) and $1,25(\text{OH})_2\text{D}$ as noted in pregnant women with normal phosphate homeostasis (102). Some data suggest that TmP/GFR is not affected by pregnancy (103), while others report rises in TmP/GFR in the first trimester (104). Intact FGF23 levels seem unaffected by pregnancy in healthy individuals, but this has not been studied in women with XLH (105). In the case of XLH, these physiological alterations may impact serum phosphorus and potentially increase pregnancy complications.

Management of maternal XLH during pregnancy and lactation. There is limited evidence to support specific guidance on the management of XLH during pregnancy and lactation. Most data are derived from case reports and case series. During pregnancy, production of $1,25(\text{OH})_2\text{D}$ from the placenta and breast increases serum calcium levels and urinary calcium excretion, warranting close monitoring (106).

Frequent laboratory testing during pregnancy (every 1-2 months) is prudent for safety monitoring. The safety of burosumab treatment during pregnancy and lactation is not established. The risks and benefits of therapy should be discussed with patients. There are inadequate data at this time to make a recommendation regarding burosumab therapy during pregnancy.

The data on mode of delivery in XLH are heterogeneous. In a report of 22 deliveries in 12 women with XLH, only 7 vaginal deliveries (32%) were reported, while the remaining required cesarean delivery (46). Similarly, a cohort study from the UK reported a higher rate of cesarean deliveries in 18 women with XLH, with 8 of 34 deliveries (23.5%) via the vaginal route (57). In contrast, a Danish study of the 60-year period from 1946 to 2006 found that only 3 of 25 women with XLH (in 5 of 36 pregnancies; 14%) underwent a cesarean delivery, not significantly different from the general population (23).

Management of maternal XLH to improve fetal outcomes.

To date, there is no evidence for any benefit to the affected fetus from treatment of maternal XLH. In the *Hyp* mouse model of XLH, the affected pups were normophosphatemic in utero despite the hypophosphatemia in the affected dam (107). It appears that FGF23 is not required to regulate fetal phosphate metabolism. Physiologic disturbances begin to affect phosphate metabolism only after birth (108). Of note, burosumab does cross the placenta, and effects on the developing fetus are not known. Close monitoring of the clinical and biochemical status of women with XLH throughout pregnancy is advised during treatment with conventional therapy, given the known effects of pregnancy on mineral homeostasis. Some clinicians reduce dosing of conventional agents during this time (109).

DENTAL and ORAL COMPLICATIONS

DENTAL RECOMMENDATIONS (NON-GRADEd)

The Panel Proposes

1. Dental visits at least once a year to screen for infections, and periodontal supportive care with recall intervals based on each individual condition.
2. In the presence of active oral manifestations, treatment with active vitamin D and phosphate salts, or burosumab

is advised to reduce the risk of dental infections and the severity of periodontitis.

RECOMMENDATIONS FOR DENTAL PROFESSIONALS (NON-GRADED)

The Panel Proposes

1. A thorough clinical and radiological assessment searching for spontaneous pulp infection (tooth color changes, fistula, swelling, abscess, cellulitis, pain, periapical bone loss), and periodontitis.
2. Performing a dental orthopantomogram (radiograph of the upper and lower jaw and teeth), potentially complimented or replaced with cone-beam computed tomography imaging, in patients with recent oral manifestations, which can be repeated based on individual needs.
3. Implant surgery may be performed after 3 to 6 months of medical treatment (conventional therapy or burosumab), which should be continued for 6 months following implant surgery; healing time should be extended up to 6 months.

Dental complications are common in patients with XLH (3, 49, 110) and significantly alter QoL (111-113). Mineralization of dentin is impaired, resulting in greater susceptibility to pulp infections (114, 115). Periodontal tissues are compromised (3, 116, 117) resulting in relatively frequent and severe periodontal diseases in affected adults of all ages (3, 118), premature loss of teeth (3, 110), as well as an increased risk of dental implant loss (47).

Prevention and Management of Dental Complications of XLH. Multidisciplinary teams caring for patients with XLH must include dental services (12, 24, 25). In adults, twice-yearly visits are indicated to perform conventional supportive periodontal therapy (24). Dental implant placement should not be performed in the absence of medical treatment. It is suggested that implant surgery be performed after 3 to 6 months of medical treatment (expert recommendation), with continuation for at least 6 months following the implant surgery (24, 119, 120). For all patients, bitewings and/or periapical radiographs, orthopantomogram or cone-beam computed tomography may be performed based on clinical needs (24, 121-123); malocclusions may be present (124). Medical therapy (with either burosumab or phosphate and active vitamin D) should be started prior to initiation of any required orthodontic treatment.

Comparison of the Effect of Therapies (Burosumab and Active Vitamin D/Phosphate Salts) on Dental Complications of XLH. Early conventional treatment with good compliance improves dentin and potentially cementum mineralization (3, 114), reduces dental infections in children and adults, and decreases the severity of periodontitis in adults (3, 49, 114, 125). Limited studies have compared the effects of burosumab with those of conventional therapy on dental manifestations of XLH in adults. In a recent RCT in adults, burosumab was not found to reduce the number of dental abscesses compared to placebo. However, dental outcomes were not included as a study endpoint measure in the study design and ascertainment was questionable (4). In this 24-week

study, 9 of the 68 adult patients (13.2%) treated with burosumab developed an abscess compared to 5 of the 66 patients (7.6%) in the placebo arm. Further long-term data is being obtained.

RESEARCH AGENDA

Much remains to be explored in terms of understanding the full adult phenotype of XLH and optimizing therapy to minimize morbidity. For instance, it is not understood which features of XLH are mediated by hypophosphatemia and which are independent of hypophosphatemia. Exploration into the direct effects of *PHEX* loss of function and chronic exposure to ambient elevations in FGF23 is warranted. On a molecular level, understanding the function of *PHEX* with respect to its substrate, its interaction with FGF23, and its full physiologic effect remains elusive and an active area of investigation. It will be important to determine whether long-term inhibition of FGF23 activity can result in normalization of bone histomorphometric measures that were found to be partially but not completely corrected after 1 year of burosumab treatment (35). Other critical gaps in knowledge include understanding the etiologies of arthritis and enthesopathy, and their responsiveness to inhibition of FGF23 activity, both acutely and with respect to long-term preventive approaches. Likewise, the therapeutic response of dental disease, hearing loss, craniosynostosis, and associated central nervous system complications remains unknown. The full burden of XLH is likely underestimated. QoL, loss of productivity, and the economic burden of the untreated XLH patient need to be estimated. On a more immediate scale, clinical experience to date would suggest optimization of treatment schedules with attention to dosing intervals is an important area to investigate, as worsening clinical symptomatology appears to recur near the end of the currently approved “every 28-day” dosing cycle. Thus, there is a broad opportunity to further improve the management of the adult patient with XLH.

Summary

These global XLH guidelines have been developed based on systematic reviews of the literature, GRADE methodology to evaluate the certainty of evidence, and broad consensus using surveys among international experts in XLH. The guidelines provide recommendations for the diagnosis and management of XLH in adults today. XLH is associated with significant multisystem complications, including musculoskeletal, dental, neurologic, renal, parathyroid, and ocular effects. A careful clinical assessment is required to confirm the correct diagnosis and to evaluate the multisystem manifestations, including the impact on daily function and QoL. A specialized multidisciplinary team is recommended to optimize care for various aspects of disease progression and to manage pharmacologic and potential surgical interventions. Conventional therapy with phosphate salts and active vitamin D is of value in improving bone mineralization and likely useful for enhancing healing of fractures, as well as preventing and treating dental complications. Complications of conventional therapy include secondary or tertiary (hypercalcemic) hyperparathyroidism, nephrocalcinosis, and impairment in renal function. Hyperparathyroidism may be less likely to occur with burosumab therapy.

Surgical intervention may be required in the presence of severe spinal stenosis, advanced scoliosis, or advanced joint disease. Medical therapy (with either burosumab or phosphate and active vitamin D) prior to surgical intervention is advised to optimize bone mineralization and surgical outcomes.

Close monitoring of any therapy during pregnancy and lactation is advised. Conventional therapy may be safe during pregnancy, although some clinicians decrease the dosing.

Burosumab has been demonstrated to improve active fracture and pseudofracture healing in comparison to placebo. In adults with fractures or pseudofractures burosumab is recommended over no therapy (strong recommendation). Burosumab is also suggested over conventional therapy in the presence of fractures or pseudofractures (conditional recommendation) based on the results of the SRs conducted. Appropriate revision of these clinical guidelines would be useful in several years with the development of a greater body of knowledge and clinical experience.

Limitations

Our recommendations are limited in assessing patients' functional status, as we primarily considered the 6-minute walking test (6MWT) for evaluating mobility. Our survey did not address other important aspects of function, such as walking perimeter, use of assistive devices, or daily activity levels. Moreover, the use of the 6MWT did not achieve the consensus threshold in our survey, reflecting variability in clinical practice.

Endorsement

To date, this manuscript has been endorsed by the following societies: The American Society for Bone and Mineral Research (ASBMR), the Argentinian society, the Brazilian Association of Bone Assessment and Osteometabolism, the Canadian XLH-Network (patient group), The Canadian Society of Endocrinology and Metabolism (CSEM), the Chilean Society of Osteology and Mineral Metabolism (SCHOMM), the Endocrine Society, the European Calcified Tissue Society (ECTS), the European Reference Network on Rare Bone Diseases (ERN BOND), the French Dental Association, the German Society of Endocrinology, the German Society of Osteology, the International Osteoporosis Foundation (IOF), the Irish Endocrine Society (IES), the Japanese Society for Bone and Mineral Research (JSBMR), the Kuwait Academy of Rare Diseases (KARD), Osteoporosis Canada, the Pediatric Endocrine Society (PES), and XLH Denmark (patient group).

Acknowledgments

The IWG greatly appreciates the following members who completed the survey: Drs. Dieter Haffner, Agnès Linglart, Outimajja Makitie, Frank Rauch, and Lars Rejnmark. We specifically acknowledge Emmett Morgante for agreeing to serve as a patient partner during the guideline development process and for sharing his perspective and feedback. We also acknowledge the patient organizations: the Canadian XLH Network for their feedback and endorsement, and XLH Denmark for endorsing the guidelines.

Funding

Solely from the Calcium disorders clinic, McMaster University, Canada.

Author Contributions

Design/conceptualization of the Project: A.A.K., D.S.A., R.M., G.G. Data acquisition, review, analysis, methodology: A.A.K., D.S.A., H.A.A., F.A., S.H., R.M., G.G. Project Administration, including acquisition of funding: A.A.K. Original drafting and preparation of the manuscript: A.A.K., D.S.A., N.M.A., T.O.C., C.C., E.A.I., S.J.d.B., P.F., R.T.A., F.A., S.S.B.N., M.B.D., R.K.C., K.D., G.F., S.F., P.G., Co.G., M.K.J., A.K., E.M.L., C.M., A.M., H.S., S.T., L.T., L.M.W., G.G., M.L.B. Review/editing of the manuscript: A.A.K., D.S.A., N.M.A., T.O.C., C.C., E.A.I., S.J.d.B., P.F., H.A.A., R.A., R.T.A., F.A., S.S.B.N., M.B.D., M.C.S., R.K.C., K.D., G.F., L.F., S.F., C.G., P.G., Co.G., Ch.G., S.H., M.K.J., S.K., A.K., A.L., W.F.L., E.M.L., C.M., R.M., E.M., A.M., A.A.P., Y.R., E.T.R., H.S., S.T., L.T., L.M.W., G.G., M.L.B.

Disclosures

A.A.K.: Speaker, advisory board (Alexion, Amgen); Speaker, advisory board, research funding (Ascendis); Advisory board, research funding (Takeda); Research funding (Amolyt, Calcilytix). **D.S.A.:** None. **N.M.A.:** Kyowa Kirin, UCB and Amgen (Consulting & advisory boards), XLH-Network Netherlands (Patient Advisory Org), Kyowa Kirin, UCB (unrestricted research grant). **T.O.C.:** Consulting & advisory boards: Ultragenyx, Kyowa Kirin; Consulting: Viridian; Research support: Ultragenyx; Other roles: Assoc. Editor JBMR, President Ped Endo Soc, Author UpToDate (royalties), XLH-Network (Patient Advisory Org); **C.C.:** Institutional research contracts with Kyowa Kirin and Novo Nordisk. **E.A.I.:** Research funding and consulting for Ultragenyx and Kyowa Kirin, Inozyme (consulting), Amgen (research funding). **S.J.d.B.:** Participation in clinical trials and consulting for Ultragenyx and consulting for Kyowa Kirin. **P.F.:** Institutional Research Grants: Ultragenyx. Advisory boards: Ultragenyx, Kyowa Kirin. **H.A.A.:** None. **R.A.:** None. **R.T.A.:** Ardylex Inc. (Research grant), Ardylex Inc, Advicenne and Ultragenyx (Consultancy). **F.A.:** None. **S.S.B.N.:** Kyowa Kirin (Research grants/consultancy/speaker/advisory board), Inozymes (consultancy), Novo Nordisk (consultancy). **M.B.D.:** Kyowa Kirin (research grants, speaker fee), Alexion (speaker fee and advisory board). **M.C.S.:** Kyowa Kirin (research grants, speaker fee). **R.K.C.:** Speaker and consultancy fees from Kyowa Kirin, advisory to UCB/Amgen. **K.D.:** Speaker: Amgen, Kyowa Kirin, Mantra Pharma. **G.F.:** Consultant: Kyowa Kirin, ProKidney, Ultragenyx, Alnylum, Speaker: ProKidney, and Ultragenyx. **L.F.:** IPSEN. **S.F.:** Kyowa Kirin (consulting). **Cl.G.:** Ascendis Pharma, Takeda and Shire (research funding). **P.G.:** None. **Co.G.:** Kyowa Kirin; Biomar, Alexion, Merck, Novo Nordisk. **Ch.G.:** Ultragenyx (unrestricted research grant, consultancy and advisory board), IPSEN, Alexion and Kyowa Kirin (consultancy). **S.H.:** None. **M.K.J.:** Funding for consultancy and speaker fees from Kyowa Kirin unrelated to this manuscript. **S.K.:** Amgen: honoraria/advisory board, Sandoz Pharmaceuticals: honoraria/advisory board, PI for XLH disease monitoring program—funded by Ultragenyx, Co-investigator TransconPTH trial funded by Ascendis. **A.K.:** None. **A.L.:** Consulting (advisory boards): Sanofi-Genzyme, Horizon, Spark Therapeutics, Ultragenyx, Biomar, Takeda-Shire, Amicus, Recordati, Alexion; Travel

grant: Sanofi-Genzyme; Research and education grants: Takeda, Sanofi, Amicus. W.F.L.: Speakers fee/advisory Boards: UCB, Amgen, Galapagos, Pfizer. E.M.L.: Consulting: Amgen; Speaker: Amgen, Ascendis; Investigator: Amgen, Ardius, Ultragenyx. C.M.: Consultancy, Travel/Research Grants or Advisory boards—Kyowa Kirin, Ascendis Pharma, Pfizer, Novo Nordisk, Biomarin, Regeneron. R.D.M., E.M., A.M.: None. A.A.P.: Kyowa Kirin (advisory board, speaker). Y.R.: Speaker: Amgen, Dawoong; Investigator: Amgen, Kyowa Kirin, Dongguk, Dong-A, Daewoong. E.T.R.: Consulted for, received honoraria from, and has research supported by Alexion Pharmaceuticals, AstraZeneca Rare Disease. H.S.: Advisory boards and/or speaker fees: Amgen, Takeda, UCB, Kyowa Kirin, Merck/Serono, Alexion, Biomarin. Research grant: Takeda; Ascendis. S.T.: None. L.T.: Clinical trial fees from Ultragenyx, NIH and PCOR grants, committees member for the Osteogenesis Imperfecta Foundation, the American Orthopaedic Association and the FDA. L.M.W.: Supported by a Tier 1 (Senior) Research Chair in Pediatric Bone Disorders from the University of Ottawa and the Children's Hospital of Eastern Ontario Research Institute; declares participation in clinical trials with Ultragenyx, and consultancy to Kyowa Kirin and Ultragenyx, and unrestricted educational grants from Ultragenyx and Kyowa Kirin (with funds to Dr. Ward's institution). G.G.: None. M.L.B.: Honoraria: Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; Grants and/or speaker: Abiogen, Alexion, Amgen, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Eli Lilly, Enterabio, Gedeon Richter, Italfarmaco, Kyowa Kirin, Menarini, Monte Rosa, SPA, Takeda, Theramex, UCB; Consultant: Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics, UCB.

Data Availability

The data supporting the findings in this study are openly available in PubMed, EMBASE, and the Cochrane databases.

Ethical Statement

The objective of this study is to evaluate the current evidence on the diagnosis and management of X-linked hypophosphatemia and did not require ethical committee approval.

References

- Liu S, Tang W, Zhou J, *et al.* Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. *J Am Soc Nephrol.* 2006;17(5):1305-1315.
- Che H, Roux C, Etcheto A, *et al.* Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. *Eur J Endocrinol.* 2016;174(3):325-333.
- Biosse Duplan M, Coyac BR, Bardet C, *et al.* Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia. *J Dent Res.* 2017;96(4):388-395.
- Insogna KL, Briot K, Imel EA, *et al.* A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. *J Bone Miner Res.* 2018;33(8):1383-1393.
- Guyatt GH, Oxman AD, Vist GE, *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;336(7650):924-926.
- Guyatt GH, Oxman AD, Kunz R, *et al.* GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol.* 2011;64(4):395-400.
- Balshem H, Helfand M, Schünemann HJ, *et al.* GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol.* 2011;64(4):401-406.
- Andrews J, Guyatt G, Oxman AD, *et al.* GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol.* 2013;66(7):719-725.
- Andrews JC, Schünemann HJ, Oxman AD, *et al.* GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. *J Clin Epidemiol.* 2013;66(7):726-735.
- Giannini S, Bianchi ML, Rendina D, *et al.* Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. *Osteoporos Int.* 2021;32(10):1937-1949.
- Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. *J Bone Miner Res.* 2011;26(7):1381-1388.
- Linglart A, Biosse-Duplan M, Briot K, *et al.* Therapeutic management of hypophosphatemic rickets from infancy to adulthood. *Endocr Connect.* 2014;3(1):R13-R30.
- Lecoq AL, Chaumet-Riffaud P, Blanchard A, *et al.* Hyperparathyroidism in patients with X-linked hypophosphatemia. *J Bone Miner Res.* 2020;35(7):1263-1273.
- Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. *Clin Sci.* 1969;37(1):23-36.
- Hartley IR, Gafni RI, Roszko KL, *et al.* Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. *J Bone Miner Res.* 2022;37(11):2174-2185.
- Haffner D, Leifheit-Nestler M, Grund A, Schnabel D. Rickets guidance: part II—management. *Pediatr Nephrol.* 2022;37(10):2289-2302.
- Fradet A, Fitzgerald J. INPPL1 gene mutations in opsismodysplasia. *J Hum Genet.* 2017;62(2):135-140.
- Tieder M, Modai D, Samuel R, *et al.* Hereditary hypophosphatemic rickets with hypercalciuria. *N Engl J Med.* 1985;312(10):611-617.
- Schlingmann KP, Ruminska J, Kaufmann M, *et al.* Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause idiopathic infantile hypercalcemia. *J Am Soc Nephrol.* 2016;27(2):604-614.
- Devuyst O, Thakker RV. Dent's disease. *Orphanet J Rare Dis.* 2010;5(1):28.
- Hohenfellner K, Rauch F, Ariceta G, *et al.* Management of bone disease in cystinosis: statement from an international conference. *J Inherit Metab Dis.* 2019;42(5):1019-1029.
- Courbebaisse M, Leroy C, Bakouh N, *et al.* A new human NHERF1 mutation decreases renal phosphate transporter NPT2a expression by a PTH-independent mechanism. *PLoS One.* 2012;7(4):e34764.
- Beck-Nielsen SS, Brusgaard K, Rasmussen LM, *et al.* Phenotype presentation of hypophosphatemic rickets in adults. *Calcif Tissue Int.* 2010;87(2):108-119.
- Haffner D, Emma F, Eastwood DM, *et al.* Clinical practice recommendations for the diagnosis and management of X-linked hypophosphatemia. *Nat Rev Nephrol.* 2019;15(7):435-455.
- Trombetti A, Al-Daghri N, Brandi ML, *et al.* Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphatemia. *Nat Rev Endocrinol.* 2022;18(6):366-384.
- Richards S, Aziz N, Bale S, *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. *Genet Med.* 2015;17(5):405-424.

27. Gaucher C, Walrant-Debray O, Nguyen T-M, Esterle L, Garabédian M, Jehan F. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. *Hum Genet.* 2009;125(4):401-411.
28. Whyte MP, Schranck FW, Armamento-Villareal R. X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children. *J Clin Endocrinol Metab.* 1996;81(11):4075-4080.
29. Borghi M, da Silva LM, Bispo L, Longui CA. A genetic study of a Brazilian cohort of patients with X-linked hypophosphatemia reveals no correlation between genotype and phenotype. *Front Pediatr.* 2023;11:1215952.
30. Beck-Nielsen SS, Brixen K, Gram J, *et al.* Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. *J Hum Genet.* 2012;57(7):453-458.
31. Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. *Bone Rep.* 2017;7:90-97.
32. Jan de Beur SM, Miller PD, Weber TJ, *et al.* Burosumab for the treatment of tumor-induced osteomalacia. *J Bone Miner Res.* 2021;36(4):627-635.
33. Bowden SA, Patel HP, Beebe A, McBride KL. Successful medical therapy for hypophosphatemic rickets due to mitochondrial Complex I deficiency induced de Toni-debré-fanconi syndrome. *Case Rep Pediatr.* 2013;2013:354314.
34. Ward LM, Rauch F, White KE, *et al.* Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna. *Bone.* 2004;34(5):905-911.
35. Insogna KL, Rauch F, Kamenický P, *et al.* Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. *J Bone Miner Res.* 2019;34(12):2183-2191.
36. Colares Neto GP, Pereira RM, Alvarenga JC, Takayama L, Funari MF, Martin RM. Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets. *Osteoporos Int.* 2017;28(5):1685-1692.
37. Funck-Brentano T, Vanjak A, Ostertag A, *et al.* Evaluation of bone density and microarchitecture in adult patients with X-linked hypophosphatemic rickets: a pilot longitudinal study. *Bone.* 2024;187:117179.
38. Shanbhogue VV, Hansen S, Folkestad L, Brixen K, Beck-Nielsen SS. Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with hypophosphatemic rickets. *J Bone Miner Res.* 2015;30(1):176-183.
39. Beck-Nielsen SS, Brixen K, Gram J, Mølgaard C. High bone mineral apparent density in children with X-linked hypophosphatemia. *Osteoporos Int.* 2013;24(8):2215-2221.
40. Ariceta G, Beck-Nielsen SS, Boot AM, *et al.* The international X-linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data. *Orphanet J Rare Dis.* 2023;18(1):304.
41. Bouzeman A, Vignot E, Derain Dubourg L, *et al.* Reassuring data on the cardiovascular risk in adults with X-linked hypophosphatemia receiving conventional therapy. *J Clin Endocrinol Metab.* 2023;109(2):e488-e494.
42. McKenna MJ, Crowley RK, Twomey PJ, *et al.* Renal phosphate handling: independent effects of circulating FGF23, PTH, and calcium. *JBMR Plus.* 2021;5(2):e10437.
43. Briot K, Portale AA, Brandi ML, *et al.* Burosumab treatment in adults with X-linked hypophosphatemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. *RMD Open.* 2021;7(3):e001714.
44. Carpenter TO. New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. *Pediatr Clin North Am.* 1997;44(2):443-466.
45. Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM. Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in hyp mice. *Calcif Tissue Int.* 2009;85(3):235-246.
46. Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. *Medicine (Baltimore).* 1989;68(6):336-352.
47. Skrinar A, Dvorak-Ewell M, Evins A, *et al.* The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. *J Endocr Soc.* 2019;3(7):1321-1334.
48. Javaid MK, Ward L, Pinedo-Villanueva R, *et al.* Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. *J Clin Endocrinol Metab.* 2022;107(3):e1249-e1262.
49. Connor J, Olear EA, Insogna KL, *et al.* Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. *J Clin Endocrinol Metab.* 2015;100(10):3625-3632.
50. Steele A, Gonzalez R, Garbalosa JC, *et al.* Osteoarthritis, osteophytes, and enthesophytes affect biomechanical function in adults with X-linked hypophosphatemia. *J Clin Endocrinol Metab.* 2020;105(4):e1798-e1814.
51. Imel EA. Enthesopathy, osteoarthritis, and mobility in X-linked hypophosphatemia1. *J Clin Endocrinol Metab.* 2020;105(7):dgaa242.
52. Portale AA, Carpenter TO, Brandi ML, *et al.* Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. *Calcif Tissue Int.* 2019;105(3):271-284.
53. Imel EA, Zhang X, Ruppe MD, *et al.* Prolonged correction of Serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. *J Clin Endocrinol Metab.* 2015;100(7):2565-2573.
54. Colares Neto GP, Ide Yamauchi F, Hueb Baroni R, *et al.* Nephrocalcinosis and nephrolithiasis in X-linked hypophosphatemic rickets: diagnostic imaging and risk factors. *J Endocr Soc.* 2019;3(5):1053-1061.
55. Nakamura Y, Takagi M, Takeda R, Miyai K, Hasegawa Y. Hypertension is a characteristic complication of X-linked hypophosphatemia. *Endocr J.* 2017;64(3):283-289.
56. Bloudeau L, Lingart A, Flammier S, *et al.* X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study. *Pediatr Nephrol.* 2023;38(3):697-704.
57. Chesher D, Oddy M, Darbar U, *et al.* Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. *J Inherit Metab Dis.* 2018;41(5):865-876.
58. Beck-Nielsen SS, Mughal Z, Haffner D, *et al.* FGF23 and its role in X-linked hypophosphatemia-related morbidity. *Orphanet J Rare Dis.* 2019;14(1):58.
59. Nielsen SR, Hansen SG, Bistrup C, Brusgaard K, Frederiksen AL. Bone deformities and kidney failure: coincidence of PHEX-related hypophosphatemic rickets and m.3243A > G mitochondrial disease. *Calcif Tissue Int.* 2022;111(6):641-645.
60. Filler G, Salerno F, McIntyre CW, *et al.* Animal, human, and ²³Na MRI imaging evidence for the negative impact of high dietary salt in children. *Curr Pediatr Rep.* 2021;9(4):110-117.
61. Tenenhouse HS, Beck L. Renal Na(+)-phosphate cotransporter gene expression in X-linked Hyp and Gy mice. *Kidney Int.* 1996;49(4):1027-1032.
62. Osorio AV, Alon US. The relationship between urinary calcium, sodium, and potassium excretion and the role of potassium in treating idiopathic hypercalciuria. *Pediatrics.* 1997;100(4):675-681.
63. Rodríguez Cuellar CI, Wang PZT, Freundlich M, Filler G. Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones. *Pediatr Nephrol.* 2020;35(3):383-397.

64. Filler G, Ahmad F, Bhayana V, Díaz González de Ferris ME, Sharma AP. Limitations of U25 CKiD and CKD-EPI eGFR formulae in patients 2–20 years of age with measured GFR>60 mL/min/1.73 m²—a cross-sectional study. *Pediatric Nephrology*. 2024; 39(4):1169–1176.
65. Schwartz GJ, Muñoz A, Schneider MF, *et al.* New equations to estimate GFR in children with CKD. *J Am Soc Nephrol*. 2009;20(3): 629–637.
66. Filler G, Lepage N. Should the schwartz formula for estimation of GFR be replaced by cystatin C formula? *Pediatr Nephrol*. 2003;18(10):981–985.
67. Webster-Clark M, Jaeger B, Zhong Y, *et al.* Low agreement between modified-schwartz and CKD-EPI eGFR in young adults: a retrospective longitudinal cohort study. *BMC Nephrol*. 2018; 19(1):194.
68. Selistre L, Rabilloud M, Cochat P, *et al.* Comparison of the schwartz and CKD-EPI equations for estimating glomerular filtration rate in children, adolescents, and adults: a retrospective cross-sectional study. *PLoS Med*. 2016;13(3):e1001979.
69. Pottel H, Hoste L, Dubourg L, *et al.* An estimated glomerular filtration rate equation for the full age spectrum. *Nephrol Dial Transplant*. 2016;31(5):798–806.
70. Inker LA, Schmid CH, Tighiouart H, *et al.* Estimating glomerular filtration rate from Serum creatinine and cystatin C. *N Engl J Med*. 2012;367(1):20–29.
71. Ikizler TA, Cuppari L. The 2020 updated KDOQI clinical practice guideline for nutrition in chronic kidney disease. *Blood Purif*. 2021;50(4–5):667–671.
72. Drawz PE, Beddhu S, Bignall ONR, *et al.* KDOQIUS commentary on the 2021 KDIGO clinical practice guideline for the management of blood pressure in CKD. *Am J Kidney Dis*. 2022;79(3): 311–327.
73. Flynn JT, Kaelber DC, Baker-Smith CM, *et al.* Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics*. 2017;140(3):e20171904.
74. Baker-Smith CM, Flinn SK, Flynn JT, *et al.* Diagnosis, evaluation, and management of high blood pressure in children and adolescents. *Pediatrics*. 2018;142(3):e20182096.
75. Sharma AP, Kirpalani A, Sharma A, *et al.* Impact of the 2022 American Heart Association pediatric ambulatory blood pressure monitoring statement on the diagnosis of hypertension. *Pediatr Nephrol*. 2023;38(8):2741–2751.
76. Portale AA, Ward L, Dahir K, *et al.* Nephrocalcinosis and kidney function in children and adults with X-linked hypophosphatemia: baseline results from a large longitudinal study. *J Bone Miner Res*. 2024;39(10):1493–1502. Doi: [10.1093/jbmr/zjae127](https://doi.org/10.1093/jbmr/zjae127)
77. O'Malley SP, Adams JE, Davies M, Ramsden RT. The petrous temporal bone and deafness in X-linked hypophosphatemia osteomalacia. *Clin Radiol*. 1988;39(5):528–530.
78. Seefried L, Smyth M, Keen R, *et al.* Burden of disease associated with X-linked hypophosphatemia in adults: a systematic literature review. *Osteoporos Int*. 2021;32(1):7–22.
79. Forestier-Zhang L, Watts L, Turner A, *et al.* Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. *Orphanet J Rare Dis*. 2016;11(1):160.
80. Lo SH, Lachmann R, Williams A, Piglowska N, Lloyd AJ. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. *Qual Life Res*. 2020;29(7): 1883–1893.
81. Ito N, Kang HG, Nishida Y, Evins A, Skrinar A, Cheong HI. Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey. *Endocr J*. 2022;69(4):373–383.
82. Yanes MIL, Diaz-Curiel M, Peris P, *et al.* Health-related quality of life of X-linked hypophosphatemia in Spain. *Orphanet J Rare Dis*. 2022;17(1):298.
83. Diaz-delCastillo M, Espersen RB, Beck-Nielsen SS, Rejnmark L, Heegaard A-M. Pain, quality of life, and mental health in adults with X-linked hypophosphatemia: a cross-sectional study. *J Clin Endocrinol Metab*. 2025;dgaf104. Doi: [10.1210/clinem/dgaf104](https://doi.org/10.1210/clinem/dgaf104)
84. Sullivan W, Carpenter T, Glorieux F, Travers R, Insogna K. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. *J Clin Endocrinol Metab*. 1992;75(3):879–885.
85. Arcidiacono T, Foligno NE, Brioni E, *et al.* Different efficacy of burosumab on physical performance and Serum phosphate in adult patients with X-linked hypophosphatemic rickets during the first six-month of treatment. *J Clin Med*. 2023;12(8):2906.
86. Ruppe MD, Zhang X, Imel EA, *et al.* Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. *Bone Rep*. 2016;5: 158–162.
87. Lecoq A-L, Schilbach K, Rocher L, *et al.* Metabolically healthy obesity in adults with X-linked hypophosphatemia. *Eur J Endocrinol*. 2024;191(2):156–165.
88. DeLacey S, Liu Z, Broyles A, *et al.* Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. *Bone*. 2019;127:386–392.
89. Yavropoulou MP, Kotsa K, Psarrakou AG, *et al.* Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. *Hormones (Athens)*. 2010;9(3):274–278.
90. Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. *Clin J Am Soc Nephrol*. 2008;3(3): 658–664.
91. Raeder H, *et al.* A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet. *Eur J Endocrinol*. 2008;159(suppl_1):S101–S105.
92. Brandi ML, Jan de Beur S, Briot K, *et al.* Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): a post hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study. *Calcif Tissue Int*. 2022;111(4):409–418.
93. Weber TJ, Imel EA, Carpenter TO, *et al.* Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. *J Clin Endocrinol Metab*. 2022;108(1):155–165.
94. Kamenicky P, Briot K, Brandi ML, *et al.* Benefit of burosumab in adults with X-linked hypophosphatemia (XLH) is maintained with long-term treatment. *RMD Open*. 2023;9(1):e002676.
95. Ali DS, Mirza RD, Alsarraf F, *et al.* Systematic review: efficacy of medical therapy on outcomes important to adult patients with X-linked hypophosphatemia. *J Clin Endocrinol Metab*. 2024;110(6):1767–1780.
96. Camp JD, McCullough JAL. Pseudofractures in diseases affecting the skeletal system. *Radiology*. 1941;36(6):651–663.
97. Ahmad F, Shah B, Nabi G, Sofi F. Looser's zone. *Oman Med J*. 2010;25(2):141.
98. Pentecost RL, Murray RA, Brindley HH. Fatigue, insufficiency, and pathologic fractures. *JAMA*. 1964;187(13):1001–1004.
99. Hamilton AA, Fitos S, Jones G, Kinsley A, Gupta RN, Lewiecki EM. Whole body, whole life, whole family: patients' perspectives on X-linked hypophosphatemia. *J Endocr Soc*. 2022;6(8): bvac086.
100. Hughes M, Macica C, Meriano C, Doyle M. Giving credence to the experience of X-linked hypophosphatemia in adulthood: an interprofessional mixed-methods study. *J Patient Cent Res Rev*. 2020;7(2):176–188.
101. Laurent MR, Harvengt P, Mortier GR, Böckenhauer D. *X-Linked Hypophosphatemia*. University of Washington; 1993.
102. Kovacs CS. Maternal mineral and bone metabolism during pregnancy, lactation, and post-weaning recovery. *Physiol Rev*. 2016;96(2):449–547.
103. Kerr C, Loken HF, Glendening MB, Gordan GS, Page EW. Calcium and phosphorus dynamics in pregnancy. *Am J Obstet Gynecol*. 1962;83(1):2–8.

104. Weiss M, Eisenstein Z, Ramot Y, Lipitz S, Shulman A, Frenkel Y. Renal reabsorption of inorganic phosphorus in pregnancy in relation to the calciotropic hormones. *BJOG*. 1998;105(2):195-199.
105. Ozsen A, Furman A, Guran T, Bereket A, Turan S. Fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein levels in healthy children and, pregnant and puerperal women. *Horm Res Paediatr*. 2020;92(5):302-310.
106. Khan AA, Clarke B, Rejnmark L, Brandi ML. MANAGEMENT OF ENDOCRINE DISEASE: hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. *Eur J Endocrinol*. 2019;180(2):R37-R44.
107. Ohata Y, Yamazaki M, Kawai M, *et al*. Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of hyp mice. *J Bone Miner Res*. 2014;29(7):1627-1638.
108. Sellars KB, Ryan BA, Hartery SA, Kirby BJ, Kovacs CS. Murine fetal Serum phosphorus is set independent of FGF23 and PTH, except in the presence of maternal phosphate loading. *Endocrinology*. 2021;162(1):bqaa202.
109. Dobrowolska-Redo A, Teliga-Czajkowska J, Sotowska A, *et al*. Pregnancy in patient with X-linked hypophosphatemic rickets—management and outcome. *Clin Exp Obstet Gynecol*. 2018;45(5):794-796.
110. Chaussain-Miller C, Sinding C, Septier D, Wolikow M, Goldberg M, Garabedian M. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. *Oral Dis*. 2007;13(5):482-489.
111. Nguyen C, Celestin E, Chambolle D, *et al*. Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration. *Endocr Connect*. 2022;11(1):e210564.
112. Herrou J, Picaud AS, Lassalle L, *et al*. Prevalence of enthesopathies in adults with X-linked hypophosphatemia: analysis of risk factors. *J Clin Endocrinol Metab*. 2022;107(1):e224-e235.
113. Gjørup H, Beck-Nielsen SS, Hald JD, Haubek D. Oral health-related quality of life in X-linked hypophosphataemia and osteogenesis imperfecta. *J Oral Rehabil*. 2021;48(2):160-168.
114. Chaussain-Miller C, Sinding C, Wolikow M, Lasfargues J-J, Godeau G, Garabédian M. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. *J Pediatr*. 2003;142(3):324-331.
115. Opsahl Vital S, Gaucher C, Bardet C, *et al*. Tooth dentin defects reflect genetic disorders affecting bone mineralization. *Bone*. 2012;50(4):989-997.
116. Coyac BR, Falgayrac G, Baroukh B, *et al*. Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia. *Bone*. 2017;103:334-346.
117. Zhang H, Chavez MB, Kolli TN, *et al*. Dentoalveolar defects in the hyp mouse model of X-linked hypophosphatemia. *J Dent Res*. 2020;99(4):419-428.
118. Ye L, Liu R, White N, Alon US, Cobb CM. Periodontal status of patients with hypophosphatemic rickets: a case series. *J Periodontol*. 2011;82(11):1530-1535.
119. Resnick D. Implant placement and guided tissue regeneration in a patient with congenital vitamin D-resistant rickets. *J Oral Implantol*. 1998;24(4):214-218.
120. James M, Roudsari RV. Prosthetic rehabilitation of a patient with X-linked hypophosphatemia using dental implants: a case report and review of the literature. *Int J Implant Dent*. 2019;5(1):15.
121. Gibson C, Mubeen S, Evans R. X-linked hypophosphatemic rickets: orthodontic considerations and management. A case report. *J Orthod*. 2022;49(2):205-212.
122. Kawakami M, Takano-Yamamoto T. Orthodontic treatment of a patient with hypophosphatemic vitamin D-resistant rickets. *ASDC J Dent Child*. 1997;64(6):395-399.
123. Makrygiannakis MA, Dastoori M, Athanasiou AE. Orthodontic treatment of a nine-year-old patient with hypophosphatemic rickets diagnosed since the age of two: a case report. *Int Orthod*. 2020;18(3):648-656.
124. Al-Jundi SH, Dabous IM, Al-Jamal GA. Craniofacial morphology in patients with hypophosphataemic vitamin-D-resistant rickets: a cephalometric study. *J Oral Rehabil*. 2009;36(7):483-490.
125. Kato H, Okawa R, Ogasawara T, *et al*. Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH. *J Clin Endocrinol Metab*. 2023;108(6):1405-1414.